Comparative Pharmacology
Head-to-head clinical analysis: INTEGRILIN versus ZONTIVITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTEGRILIN versus ZONTIVITY.
INTEGRILIN vs ZONTIVITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by preventing fibrinogen binding.
ZONTIVITY (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist that inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. It does not directly inhibit thrombin activity but blocks thrombin-mediated platelet activation.
Acute coronary syndrome: IV bolus of 180 mcg/kg, followed by continuous IV infusion of 2 mcg/kg/min for up to 72 hours. Percutaneous coronary intervention: IV bolus of 180 mcg/kg immediately before PCI, followed by continuous IV infusion of 2 mcg/kg/min for up to 18-24 hours, with a second 180 mcg/kg bolus 10 minutes after the first.
1 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: ~2.5 hours (2-3 hours) after intravenous administration; clinical context: rapid clearance allows return of platelet function within 4 hours after infusion cessation.
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment.
Renal: ~50% as unchanged drug and metabolites, Biliary/fecal: minimal; total clearance approximately 55-58% renal.
Primarily as unchanged drug via renal excretion (approximately 80%) and fecal/biliary elimination (approximately 20%).
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent